Levofloxacin Reiwa Healthcare (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing DNA supercoiling and strand separation, it halts bacterial cell division and leads to bacterial death, providing a bactericidal effect against a wide range of Gram‑positive and Gram‑negative organisms.

The dosage of Levofloxacin Reiwa Healthcare is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local guidelines. The prescriber sets the exact dose, frequency, and duration of therapy.

Safety of levofloxacin in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Levofloxacin offers broad‑spectrum coverage, including many resistant strains, and can be administered intravenously for severe infections. Compared with beta‑lactams, it may have a faster bactericidal effect but carries specific risks such as tendon toxicity and QT prolongation, requiring careful patient selection.

Levofloxacin Reiwa Healthcare should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct light, and avoid exposure to extreme temperatures to maintain stability.

Levofloxacin Reiwa Healthcare is given by intravenous infusion under the supervision of a healthcare professional. The infusion rate and duration are set by the prescriber and nursing staff, following aseptic technique and appropriate monitoring during administration.

Serious risks include tendon rupture (especially Achilles), QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, and potential central nervous system effects like seizures. Patients should be educated to report any sudden tendon pain, palpitations, or skin reactions immediately.

Levofloxacin should be avoided in patients with known hypersensitivity to fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, significant QT prolongation, or those receiving concomitant medications that markedly increase the risk of tendon rupture or cardiac arrhythmias. Clinical judgment is essential.